Cardiometabolic Disorders
CNBC Fast Money
CEO David Hallal discusses Scholar Rock’s cardiometabolic program and results from the Phase 2 EMBRAZE Trial
Positive Phase 2 EMBRAZE Trial Results Demonstrated Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss
“We are pleased that the EMBRAZE trial accomplished its objective by achieving its primary endpoint. The results validated our hypothesis that our platform of highly selective myostatin inhibitors has the potential to support healthier weight loss for millions of patients on GLP therapies by safely preserving lean mass.”
Akshay Vaishnaw, M.D., Ph.D.
President, R&D
Scholar Rock announced topline results of the EMBRAZE trial in June 2025. The EMBRAZE trial was designed to assess the ability to preserve lean body mass associated with tirzepatide-induced weight loss in patients with obesity or overweight.
Topline results successfully demonstrated proof-of-concept for a highly selective, anti-myostatin antibody to preserve lean mass, thus improving the quality of weight loss with tirzepatide therapy.
The EMBRAZE trial data demonstrated:
Patients receiving apitegromab with tirzepatide over 24 weeks showed a 54.9% preservation of lean mass (+4.2 lbs of lean mass) versus tirzepatide alone (p=0.001)
Patients receiving apitegromab with tirzepatide over 24 weeks lost 18.8 lbs of fat mass while those on tirzepatide alone lost 17.7 lbs of fat mass
Patients receiving apitegromab with tirzepatide over 24 weeks lost 12.3% of body weight while those on tirzepatide alone lost 13.4% of body weight
Higher quality of weight loss observed for patients receiving apitegromab with tirzepatide (85% fat mass/15% lean mass) compared to tirzepatide alone (70% fat mass/30% lean mass)
Apitegromab was generally well tolerated, and the encouraging safety profile was consistent with the safety profile observed in prior clinical studies
